On August 26, Hansoh Pharma announced its interim results for the first half of 2020, with revenue of approximately RMB 3.98 billion, a year-on-year decrease of 13.5%; profit of approximately RMB 1.222 billion, a year-on-year decrease of 16.5%. R&D expenses amounted to RMB 476 million, a year-on-year decrease of 14.60%.
Hansoh Pharma focuses primarily on central nervous system disorders, oncology, anti-infectives, and other therapeutic areas. Financial reports indicate that while total revenue declined year-on-year amid the impact of the COVID-19 pandemic and the volume-based procurement (VBP) policy, revenue from newly launched products grew rapidly.
Currently, Hansoh Pharma has over 100 projects under development, including five innovative drugs in Phase II clinical trials and beyond, and 22 items undergoing human bioequivalence (BE) studies (including production applications). In the first half of the year, Hansoh Pharma submitted 10 new clinical trial applications and obtained approvals, filed 10 marketing authorization applications, and received approval for six new drugs (including one innovative drug and two first-to-market generics). All generic drugs have passed the consistency evaluation.
Among these, Ameile is China’s first independently developed third-generation innovative EGFR-TKI drug. It has been approved for marketing and is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior EGFR-TKI therapy and are T790M mutation-positive. Ameile has demonstrated favorable efficacy and safety profiles, including effectiveness in patients with brain metastases. The independently developed innovative drug HS-10234 is expected to submit a New Drug Application (NDA) in Q3 2020. This agent is indicated for the treatment of hepatitis B, offering improved efficacy and significantly reduced toxic side effects compared to the previous-generation drug (TDF).
In addition to internal R&D investment, Hansoh Pharma is also actively seeking external collaboration and acquisition opportunities. In July, it entered into a strategic partnership and licensing agreement with EQRx, granting EQRx the overseas rights for the research, development, manufacturing, and commercialization of almonertinib. To strengthen its pipeline, Hansoh Pharma in-licensed two new drug projects: an innovative anti-infective project from NiKang Therapeutics in April, and a fourth-generation Bcr-Abl inhibitor project from TuoZhen Pharmaceutical in July. Regarding external collaborations, in April, Hansoh Pharma expanded its partnership with Atomwise on AI-assisted drug design for the discovery of active compounds.